Stocktoria
Turn Therapeutics Inc. TTRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-10-08
Turn Therapeutics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 |
|---|---|---|
| R&D expense | $265,570 | $245,956 |
| Operating income | -$5.9M | -$1.8M |
| Net income | -$3.2M | -$1.8M |
| EPS (diluted) | $-0.12 | $-0.07 |
| Operating cash flow | -$2.6M | -$1.4M |
| Cash & equivalents | $4.0M | $498,286 |
| Total assets | $12.2M | $2.0M |
| Total liabilities | $7.5M | $2.2M |
| Shareholders' equity | $4.7M | -$177,432 |
Source: SEC EDGAR filings · CIK 0002023016 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.